Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.24    -0.01 (-4.00%)
Bid:
0.23
Ask:
0.25
Spread: 0.02 (8.696%)
Market Cap: £13.91m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Director / PDMR Shareholding

18 Nov 2022 07:00

RNS Number : 8357G
CAP-XX Limited
18 November 2022
 

18 November 2022

CAP-XX Limited

("CAP-XX" or the "Company")

Director / PDMR Shareholding

CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, announces that, on 16 November 2022, Steen Feldskov, Non-Executive Director, bought 315,787 ordinary shares of no par value in the Company ("Ordinary Shares") at a price of 3.164 pence per Ordinary Share.

Following the above purchase, Steen Feldskov now has a total beneficial interest in 425,000 Ordinary Shares, equivalent to approximately 0.1 per cent. of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation (which forms part of Domestic UK Law pursuant to the European Union (Withdrawal) Act 2018) can be found below.

For further information contact:

 

CAP-XX Limited

Anthony Kongats (Chief Executive Officer) +61 (0) 2 9428 0139

 

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Alex Brearley (Corporate Finance) +44 (0) 20 3328 5656

Tony Quirke (Sales and Corporate Broking)

 

Cenkos Securities plc (Joint Broker)

Neil McDonald / Pete Lynch +44 (0) 13 1220 6939

 

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

 

 

More information is available at www.cap-xx.com

 

About CAP-XX

CAP-XX (LSE:CPX) is a world leader in the design and manufacture of ultra-thin prismatic and compact cylindrical supercapacitors. Its prismatic supercapacitors are manufactured in Australia and Malaysia and its cylindrical supercapacitors are manufactured in China. The company's strong intellectual property (IP) portfolio includes 11 patent families. CAP-XX's ultra-thin prismatic supercapacitors are ideal for space-constrained electronics applications where small energy storage device size and thickness are important. The unique feature of CAP-XX supercapacitors is their very high-power density and high-energy storage capacity in space-efficient thin prismatic and compact cylindrical packages. For more information, visit https://www.cap-xx.com/ or email sales@cap-xx.com.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Steen Feldskov

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

CAP-XX Limited

b)

LEI

213800HECUSIYXH3WN26

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of no par value each in CAP-XX Limited

 

Identification code (ISIN) for CAP-XX Limited ordinary shares: AU0000XINAS1

 

b)

Nature of the transaction

Purchase of ordinary shares

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3.164 p

315,787

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

16 November 2022

f)

Place of the transaction

London Stock Exchange, XLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBKOBKKBDBBDD
Date   Source Headline
2nd Feb 20267:00 amRNSInterim Results
23rd Jan 20267:00 amRNSNotice of Interim Results & Investor Presentation
19th Dec 202510:13 amRNSReceipt of R&D tax credit
19th Dec 202510:13 amRNSReceipt of R&D tax credit
10th Dec 20252:16 pmRNSHolding(s) in Company
28th Nov 20255:00 pmRNSTotal Voting Rights
28th Nov 202510:13 amRNSResult of AGM
14th Nov 20257:00 amRNSIssue of Shares and Director/PDMR Shareholding
10th Nov 20257:00 amRNSDirector/PDMR Shareholding
7th Nov 20257:00 amRNSFinal results and notice of AGM
30th Oct 20251:02 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20257:00 amRNSImplementation of Warehouse Management System
10th Sep 202511:48 amRNSHolding(s) in Company
7th Aug 20257:00 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDesign Win with Global Semiconductor Manufacturer
31st Jul 20255:00 pmRNSTotal Voting Rights
25th Jul 20257:00 amRNSHolding(s) in Company
18th Jul 20257:00 amRNSUpdate re. collaboration with SCHURTER
2nd Jul 20257:00 amRNSHolding(s) in Company
1st Jul 20257:29 amRNSIssue of Shares and Director/PDMR Shareholdings
30th Jun 20257:00 amRNSGlobal Distribution Agreement with RS Group plc
9th Jun 20257:00 amRNSBusiness Update and Appointment of Interim CFO
30th May 202510:32 amRNS-RUpdated website
13th May 202511:31 amRNS-RDesign Win with Multinational Conglomerate
30th Apr 20251:57 pmRNSChange of Auditor
26th Mar 20257:00 amRNSGrant of share options
19th Mar 20257:00 amRNSChange of Board Structure and Grant of Options
18th Mar 20259:35 amRNSGlobal Distribution Agreement with Premier Farnell
12th Mar 20252:43 pmRNSTechnology Cooperation Agreement with SCHURTER
7th Mar 20257:00 amRNSMaster Distribution Agreement with Waldom
17th Feb 20257:00 amRNSHalf-year Results
11th Feb 20257:00 amRNSNotice of Interim Results & Investor Presentation
31st Jan 20255:00 pmRNSTotal Voting Rights
21st Jan 20254:27 pmRNSIssue of Shares and Director/PDMR Shareholding
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
17th Jan 20257:00 amRNS-RDistribution agreement with JM Elektronik
15th Jan 20257:00 amRNSFirst shipment to SCHURTER AG
13th Jan 202511:29 amRNSResult of AGM
7th Jan 20257:00 amRNSManagement and board changes
31st Dec 20241:00 pmRNSTotal Voting Rights
9th Dec 202410:19 amRNSNotice of AGM
5th Dec 20248:18 amRNSResult of General Meeting
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20249:57 amRNSDirectors' Subscription
29th Nov 20247:00 amRNSAudited results for the year ended 30 June 2024
5th Nov 20247:00 amRNSResult of Retail Offer, Notice of GM and TVR
1st Nov 20247:00 amRNSResult of Placing
31st Oct 20244:40 pmRNSRetailBook Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.